Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In an era where medicine is increasingly underpinned by a molecular understanding of disease and an evolving evidence base for best practice, the concept of personalised medicine, where treatment selection for each patient becomes individualised, has gained momentum1. The ability to individualise a patient’s care has become a particularly pressing issue in the field of cancer therapeutics as there is a growing recognition that both the global incidence of cancer is steadily rising and the associated costs in terms of treatment and lost productivity are ever increasing. Advances in molecular profiling, which allow the typing of cancers according to their gene expression profile, have made it possible to identify biomarkers that have the potential to allow risk stratification of patients into disease-and treatment-specific subgroups.

Type

Journal article

Journal

European Drug Target Review

Publication Date

01/05/2014

Volume

1

Pages

41 - 44

Total pages

3